Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation–Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma

References

Page 1

	Year	Citations
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, New England Journal of Medicine	2017	5.7K
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma Thierry Philip, Cesare Guglielmi, Anton Hagenbeek, New England Journal of Medicine	1995	2.4K
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas Stephen J. Schuster, Jakub Svoboda, Elise A. Chong, New England Journal of Medicine	2017	1.8K
High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation Stephanie J. Lee, John P. Klein, Michael Haagenson, Blood	2007	1.2K
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma Ajay K. Gopal, Brad S. Kahl, Sven de Vos, New England Journal of Medicine	2014	1K
<sup>131</sup>I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma Mark Kaminski, Melissa Tuck, Judith Estes, New England Journal of Medicine	2005	714
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation Stephen Robinson, Anthony H. Goldstone, Stephen Mackinnon, Blood	2002	387
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma Martin Dreyling, Armando Santoro, Luigina Mollica, Journal of Clinical Oncology ImmunologyPathologyPi3k InhibitorPharmacotherapyImmunotherapy	2017	386
Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning Frédéric Baron, Michael B. Maris, Brenda M. Sandmaier, Journal of Clinical Oncology	2005	333
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab Issa F. Khouri, Peter McLaughlin, Rima M. Saliba, Blood	2008	293

Page 1